Navigation Links
Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
Date:1/7/2008

SAN DIEGO, Jan. 7 /PRNewswire/ -- Trius Therapeutics, Inc. announced today that it initiated its first Phase 1 clinical trial of TR-701, an antibacterial drug candidate intended for treatment of patients with serious Gram-positive bacterial infections, including those caused by MRSA and other drug-resistant strains. The eighty-eight subject single and multiple ascending dose trial will test tolerability, safety and pharmacokinetics of the oral dosage form of the drug and will compare its properties to those of Zyvox(R), the only marketed drug in the oxazolidinone class.

"In this early clinical trial our goal is to demonstrate the potential of TR-701 to provide patients and clinicians with more convenient dosing and a broader safety margin than the current standard of care," stated Jeffrey Stein,

Ph.D., President and CEO of Trius Therapeutics. "TR-701's potential for once-daily dosing, supported by results of prior exploratory human testing in Korea and preclinical animal data, is expected to translate into an increased therapeutic index and thereby provide an important option for the treatment of serious infections caused by drug-resistant bacterial pathogens."

"Because the majority of bacterial infections in the hospital are now caused by bacteria resistant to many antibiotics, and such infections are also spreading alarmingly within the community, there is an ever growing need for potent yet safe orally available drugs to treat infections caused by resistant Gram-positive pathogens," stated Philippe Prokocimer, M.D., Chief Medical Officer of Trius. "We believe that TR-701 has the potential to become a first-line, best-in-class, treatment for infections caused by these pathogens."

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by resistant pathogens. The company's lead product candidate, TR-701 is a novel oral and IV oxazolidino
'/>"/>

SOURCE Trius Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
2. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
3. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
4. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
5. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
6. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
7. Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectious Diarrhea
8. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
9. Senesco Technologies Initiates Preclinical Studies for Cancer Target
10. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
11. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...lif., Nov. 25 ChemoCentryx, Inc....from the Company,s PROTECT-1 (the Prospective Rand...Trial) of Traficet-EN(TM) (CCX282-B) in patients w...d clinical efficacy with a favorable safety and to...ce of clinical efficacy in the reduction of diseas...
(Date:11/24/2009)...Nov. 24 Endologix, Inc. ...treatments for aortic disorders, announced today t...all proceedings in, the patent infringement lawsui... The motion was filed in the United States Distri... has requested that the stay remain in effect whil...
(Date:11/24/2009)...24 Anadys Pharmaceutical...ill present at the 21st Annual Piper Jaffray Healt...:00 a.m. EST (6:00 a.m. PST). The conference is b...land, Ph.D., President and Chief Executive Officer... its clinical development programs, ANA598 and ANA...
Breaking Medicine Technology:ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 6Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2Blood Tests May Spot Colon Cancer 58044 1Blood Tests May Spot Colon Cancer 58044 2Blood Tests May Spot Colon Cancer 58044 3Blood Tests May Spot Colon Cancer 58044 4Prix Galien USA to Launch a Health Care Dialogue Among World Leading Innovators in Science Economics and Biotech 58040 1Prix Galien USA to Launch a Health Care Dialogue Among World Leading Innovators in Science Economics and Biotech 58040 2SoluLinK Introduces Product that Links All Biomolecules Greater Than 20 Times Faster with 100 25 Yields 14215 1SoluLinK Introduces Product that Links All Biomolecules Greater Than 20 Times Faster with 100 25 Yields 14215 2
...wing the candidate vaccine induced neutralizing a...ERFIELD, Ill., June 11 Baxter International,Inc. ..., 2008 issue of The,New England Journal of Medicin...avian influenza (H5N1) vaccine, CELVAPAN, met Phas...ty (generating a functional immune,response). This...
...JOLLA, Calif., June 11 Duska Therapeutics,Inc. (O...), announced today,that it has been granted an exc... Johns Hopkins University to develop and commercia...l cardiovascular drugs for the,treatment of heart ...s,expected to enter a Phase II clinical study late...
Other Medicine Technology:The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine 2The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine 3The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine 4The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine 5Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins 2Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins 3
(Date:11/28/2009)... lift spirits, recognize signs of depression , ... many seniors, the holiday season can trigger mela...le with health issues or worry about money problem..., To help overcome the seasonal blues, the AGS F... advice: , Get out and socialize or invite famil...
(Date:11/27/2009)...v. 27 /PRNewswire/ - Uploadable USB pedometers may...wellness. A combination of advanced accelerometer ...g a long term concern over the accuracy of self-re... and reward improved participation in a fitness pr... first wellness suppliers to integrate this techno...
(Date:11/27/2009)...7 Considered a highly r...ears ago, solid organ transplantation is now a lif...rdinary men and women who gathered at the Winspear...gether from medical centers around the world to ce...ansplant Institute (BRTI), one of the pioneers of ...
(Date:11/27/2009)...., Nov. 27 Preventing d...nd fortunately every year, new vaccines are being ...vaccines boost immunity for the same period of tim..., needed to keep immunity strong? ,, In this ...erican Academy of Pediatrics, Michael Pichichero M...
(Date:11/27/2009)... Israel, Nov. 27 Shamir ...), a leading provider of innovative products and t... today that its board of directors had declared a ...$ 10 million (approximately NIS 37.62 million base...exchange), or approximately US$ 0.609 (approximate...
Breaking Medicine News(10 mins):Health News:Seniors May Need Help Overcoming Holiday Blues 2Health News:New USB technology adds accountability and convenience to wellness programs 2Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 2Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 3Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3
...ke, , , WEDNESDAY, Dec. 24 (HealthDay New...ich can be a particular concern for people managin...ociate chairwoman for integrated medicine and psyc...ffered in a news release from the university, incl...
...enver (DU) Associate Professor Rene Botta suggests...ate students to wash their hands more frequently a...7, researchers posted messages in the bathrooms of... vivid graphics and photos. The messages resulted ...
...asier time quitting may have the benefit of specif...ew study by a team of federal scientists at the Na... Manhasset, NY (Vocus) December 23, 2008 -...al scientists at the National Institute on Drug Ab...
... treating gum disease in patients who have diabete...l scaling is linked to 10 to 12 percent lower medi...ing but the study was not designed to firmly estab... U-M School of Public Health. Taylor led the resea...
...man Services recently awarded Jefferson Hospital f...ving a lifesaving organ donation conversion rate o...eriod. The award was given during the fourth Nati...k tirelessly to ensure their patients are receivin...
... inflammation in perihepatic capsules with concomi...per abdomen appeared as the main symptom. These ca...ases for which the major symptom is pain in the ri... by antibiotic therapy. Nevertheless, without suff...
Other Medicine News:Health News:University of Denver uses 'gross' messaging to increases handwashing, fight Norovirus 2Health News:Studies on Smoking Genes and Transcriptional Control of Chronic Fatigue Syndrome Revealed in Molecular Medicine 2Health News:Treating gum disease linked to lower medical costs for patients with diabetes 2Health News:Jefferson Hospital for Neuroscience receives Department of Health and Human Services award 2Health News:What is the clinical character of Fitz-Hugh-Curtis syndrome? 2
Siemens Webcast
Siemens Webcast: Legislative Developments Impacting Cardiology Services Reimbursement
...ny pH catheters are designed for patient comfort a...re number marked at 5cm intervals and line marked ...models are available spanning most clinical needs ...e models with one or two sensors., ,Flexilog sing...
...ny pH catheters are designed for patient comfort a...re number marked at 5cm intervals and line marked ...models are available spanning most clinical needs ...e models with one or two sensors., ,A range of fo...
Medicine Products: